VANCOUVER, British Columbia, April 09, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), ("Rakovina" or the "Company"), a biopharmaceutical company dedicated to improving the lives of cancer patients through the development of novel DNA-damage response inhibitor therapeutics, is pleased to announce that members of the Company's scientific team presented new data on the Company's novel kt-3000 series at the American Association of Cancer Research (AACR) Annual Meeting at the San Diego Convention Center.
In the presentation entitled, "Pharmacological Synthetic Lethality by Co-Inhibition of PARP and HDAC Enzymes" during yesterday's Late Breaking Experimental and Molecular Therapeutics Research session at the conference, Rakovina discussed conceptual insights on how co-inhibition of these enzymes can eliminate cancer cells with an intact DNA repair machinery.
"We are very proud of our continued progress in our quest to find new treatments for cancer," said Rakovina Executive Chair Jeffrey Bacha. "The research was led by our President and Chief Science Officer Dr. Mads Daugaard, and we continue to be highly encouraged about the direction of our pre-clinical research."
"The combination of PARP and HDAC inhibition activity in one single drug candidate showed strong anti-tumor cell activity in DNA repair-proficient cells where single agent PARP inhibitors have limited effects," said Dr. Daugaard. "Our research continues to support the idea that the development of bifunctional PARP-HDAC inhibitors may provide a novel therapeutic opportunity for tumors with resistance to first-generation PARP inhibitors."
According to Bacha, first-generation PARP inhibitors have become an important standard-of-care in the treatment of several major solid tumors, including subsets of breast, lung and prostate cancers, generating nearly USD $3 billion in annual revenue. Resistance to PARP inhibitors develops over time so continued innovation is needed to meet the need for new and better treatments.
Dr. Daugaard said, "Lead candidates from our kt-3000 series dual-function PARP-HDAC inhibitors demonstrate the ability to overcome resistance to treatment and potentially treat cancers that would normally respond poorly to treatment with first-generation PARP inhibitors (such as Ewing Sarcoma, or any other DNA repair-proficient types of cancer). This novel approach not only addresses the unmet need, but also opens the door to potentially treat a wide range of cancers currently outside the scope of the first-generation PARP inhibitors."
Development of Rakovina Therapeutics' kt-3000 series is supported, in part, by the St. Baldrick's Foundation Martha's BEST Grant for All, which is aimed at developing new treatments for Ewing sarcoma, an aggressive bone and soft tissue cancer in children and young adults.
Collaborators on this project include the Vancouver Prostate Centre, Vancouver, Canada; Rakovina Therapeutics, Vancouver Canada; the Department of Urologic Sciences, the Department of Pathology and Laboratory Medicine and the Department of Urologic Sciences, University of British Columbia, Vancouver, Canada.
The AACR is celebrating its 115th year and expects over 21,000 attendees from around the world.
The Company recently announced a strategic evolution in its business model that places Rakovina at the forefront of artificial intelligence-driven (AI), precision research for cancer drug development. (See press release of March 27, 2024.)
About Rakovina Therapeutics Inc.
Rakovina Therapeutics Inc. is focused on the development of new cancer treatments based on novel DNA-damage response technologies. The Company leverages a proprietary AI drug discovery platform to support the development of novel DNA-damage response inhibitors with the goal of advancing multiple drug candidates into human clinical trials in collaboration with pharmaceutical partners. Rakovina's overarching mission is to significantly enhance outcomes for cancer patients by delivering effective therapeutics, approved by regulatory agencies such as Health Canada, the United States Food and Drug Administration, and other international bodies.
Further information may be found at .
For Additional Information Contact:
Rakovina Therapeutics Inc.
David Hyman
Chief Financial Officer
Email: info@rakovinatherapeutics.com
Investor Relations Contact:
ir@rakovinatherapeutics.com
Media Contact:
media@rakovinatherapeutics.com
The TSXV has neither approved nor disapproved the content of this press release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
Notice of Forward-Looking Statements
This release includes forward-looking statements regarding the Company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the Company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of the Company.
The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally and risks associated with growth and competition.
Although the Company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward- looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the Company's most recent filings on SEDAR for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the Company's profile page at .
